• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

European Society of Cardiology Congress 2021: Primary Care Preview


The ESC Congress 2021, Aug 27-30, 2021, is here. For primary care, we highlight the "Hot Lines" clinical trial presentations where new data from novel trials will premier.

The European Society of Cardiology (ESC) Congress -- The Digital Experienced, begins on Friday, August 27 and runs through Monday, August 30. The all-virtual program offers 15 topic "channels" to choose from every day, from Arrhythmias and Device Therapy and COVID-19 to Preventive Cardiology and Valvular, Myocardial, Pericardial, Pulmonary, and Congenital Heart Disease.

Of interest to the primary care audience will be the Hot Lines clinical trial presentation sessions, reserved for first presentation of the primary endpoint(s) of novel clinical trials, recently completed and unpublished.

Just 20 studies were accepted as Hot Lines for ESC 2021 and are spread across the 4 days in dedicated sessions. Trial topics this year cover the entire field of cardiology, from prevention, to arrhythmias, to intervention, to antithrombotic therapy.”

The following slide show provides a preview of the new studies, at-a-glance, including the time and day of the presentation. More than one will pique your curiosity!

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.